Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

November 28, 2000; 55 (10) Articles

The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome

Marinos C. Dalakas, Mavis Fujii, Mian Li, Beverly McElroy
First published November 28, 2000, DOI: https://doi.org/10.1212/WNL.55.10.1531
Marinos C. Dalakas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mavis Fujii
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mian Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beverly McElroy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome
Marinos C. Dalakas, Mavis Fujii, Mian Li, Beverly McElroy
Neurology Nov 2000, 55 (10) 1531-1535; DOI: 10.1212/WNL.55.10.1531

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
2768

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate the clinical spectrum of anti-GAD-positive patients with stiff-person syndrome (SPS) and provide reproducible means of assessing stiffness.

Background: SPS can be difficult to diagnose. Delineation of the clinical spectrum in a well defined population will increase diagnostic sensitivity.

Methods: In 20 anti-GAD-positive patients with SPS (six men, 14 women), screened among 38 referred patients, the authors assessed symptoms and signs, degree of disability, associated conditions, and immunogenetic markers. Degree of bending, distribution of stiff areas, timed activities, and magnitude of heightened sensitivity were examined monthly for 4 months in five patients.

Results: Average age at symptom onset was 41.2 years. Time to diagnosis was delayed from 1 to 18 years (mean 6.2). Stiffness with superimposed episodic spasms and co-contractures of the abdominal and thoracic paraspinal muscles were characteristic. All had stiff gait and palpable stiffness in the paraspinal muscles. Stiffness was asymmetric or prominent in one leg in 15 patients (stiff-leg syndrome) and involved facial muscles in 13. In one patient spasms lasted for days (status spasticus). Twelve patients needed a cane and seven a walker due to truncal stiffness and frequent falls (average three to four per month). Distribution of stiffness and degree of heightened sensitivity were two reproducible indices of stiffness and spasms. Autoimmune diseases or autoantibodies were noted in 80% and an association of with DRβ1 0301 allele in 70%.

Conclusions: SPS is 1) frequently misdiagnosed due to multifaceted presentations and asymmetric signs, 2) disabling if untreated, and 3) associated with other autoimmune conditions.–1535

Stiff person syndrome (SPS) is a rare CNS disorder characterized by fluctuating muscle rigidity of truncal and proximal limb muscles with superimposed spasms.1-4⇓⇓⇓ It is mostly a clinical diagnosis, facilitated by a high degree of suspicion, due to a lack of disease-specific neurologic signs and laboratory tests. The electromyographic signs of simultaneous voluntary contraction of the agonist and antagonist muscles, although helpful when the disease is suspected, are not specific.5-7⇓⇓ The recently identified disease variants8,9⇓ and the superimposed strong functional component4 further complicate the diagnostic uncertainty. Because SPS, if untreatable, can be serious and lead to total body rigidity, objective clinical and laboratory means are essential for diagnosis and therapy.

To highlight the complexities in clinical presentation, define the clinical spectrum of the disease, and examine reproducible means of assessing stiffness, we studied 20 patients with SPS selected based on anti–glutamic acid decarboxylase (anti-GAD) antibody positivity. Even though autoantibodies against GAD may be present in only 60% of patients with SPS,10-13⇓⇓⇓ their presence at high titers is expected to define a clinically more homogeneous group.

Methods.

Patient selection.

Twenty patients were selected among 38 referred to the Neuromuscular Diseases Section of the NIH based on the following recently revised criteria4: 1) insidious onset of muscular rigidity in the limbs and axial (trunk) muscles, most prominent in the abdominal and thoracolumbar paraspinals, with difficulty in turning or bending; 2) continuous co-contraction of agonist and antagonist muscles with inability to relax, as confirmed clinically and electrophysiologically; 3) episodic spasms superimposed on the rigidity and precipitated by unexpected noises, tactile stimuli, or emotional upset; and 4) absence of any other neurologic disease or chronic pain syndromes that could explain stiffness and rigidity.

All patients were positive for anti-GAD antibodies assessed by immunocytochemistry on frozen sections of rat cerebellum,3 by Western blot on purified or recombinant GAD 65, as reported,13 and by an ELISA assay using commercially available kits (from Boehringer Mannheim, Germany). Positive samples by ELISA were those with antibody titers more than 50 ng/mL, a cut-off level 50-fold higher than the low anti-GAD antibody levels noted in patients with insulin-dependent diabetes mellitus (IDDM).13 The patients who fulfilled the above inclusion criteria were admitted to the NIH Clinical Center after signing an informed consent.

Clinical examination and search for stiffness-related factors.

Detailed neurologic examination was performed on all patients. History regarding symptomatology, factors influencing daily fluctuations, frequency and conditions of falling, ability to work or carry out daily activities, history of concurrent medical or psychiatric illnesses, and family history of autoimmune diseases were explored. The degree of disability was determined by the patient’s need for assistive devices such as a walker or cane. Forced discontinuation from work due to SPS symptomatology was also noted.

Immunologic and immunogenetic studies.

A search for the following autoantibodies was performed: antithyroid, antiparietal cell, anti-intrinsic factor, antinuclear antibody, rheumatoid factor, anti-RNP, anti-SSA (RO), anti-SSB (La), anti-SM, antistriated muscle, antimicrosomal, anti-Jo-1, antimitochondrial, and GM1. Total serum immunoglobulins and immunofixation electrophoresis were also examined.

Human leukocyte antigen (HLA) class II allele-specific oligonucleotide typing was performed in genomic DNA extracted from peripheral blood by the NIH clinical laboratory in 18 patients, using PCR sequence-specific primer mixture for 71 alleles contained in the DQ β1 and DR β1, DR β3, DR β4, and DR β5 loci, based on the method of Park and Tonai.15

Sequential measurements of stiffness.

To assess reproducibility of various indices that may best capture stiffness and episodic spasms, we used the data collected monthly for 4 consecutive months in five patients randomized to placebo during their participation in a controlled clinical trial. The following indices were examined, as close as possible to the same time of day.

Degree of stiffness.

Bending at the waist. With the patients standing against the wall and their palms rested on the anterior or lateral aspect of each thigh, we measured the distance from the top of the middle finger to the floor before (A) and after bending at the waist and laterally on each side trying to touch the floor (B). The ratio of B/A defined the degree of flexibility.

Chest expansion.

The difference during deep inhalation (B) and full exhalation (A) at the nipple line was measured.

Distribution of stiffness.

This was rated by the physician according to the number of stiff areas as follows: 0, no stiff areas; 1, stiffness of the lower trunk; 2, stiffness of the upper trunk; 3, stiffness of both legs; 4, stiffness of both arms; 5, stiffness of the face; and 6, stiffness of the abdomen and back.

Heightened sensitivity: spasms and falls.

The distribution of muscle spasms, their frequency, and sensitivity to stimuli were recorded by the examining physician in each monthly visit. Stimuli that trigger or increase stiffness, such as open spaces, anxiety, crowds, unexpected noises, approaching cars, and sense of a hurry, were recorded. The frequency of falls and the events predisposing to falls were also noted. The magnitude of heightened sensitivity was measured according to the induction of stiffness and spasms by the following factors: noise (1); visual stimuli (2); somatosensory stimuli (3); voluntary activities (4); emotional upset or stress (5); untriggered (6); and awakenings due to nocturnal spasms (7). The maximum score of 7 was the total score of heightened sensitivity.

Timed activities.

The time needed to perform the following tasks as quickly as possible was recorded with a stopwatch: 1) rising from a chair; 2) walking a 30-foot length of corridor three times; 3) turning 180° with feet together, clockwise and counterclockwise; and 4) going up and down four standard stairs.

Results.

Clinical observations.

Symptoms.

The average age at diagnosis was 41.2 years and the average time from symptom onset to diagnosis was 6.2 years (range 1 to 18 years). The patients were 6 white men and 14 women (three African American); hence the more appropriate term “stiff-person syndrome.” The number of falls averaged three to four per month. One patient had become bedridden. Two sets of symptoms predominated, muscular rigidity (stiffness) and episodic spasms superimposed on the rigidity.

The rigidity, characterized by tightness and stiffness, began insidiously in the axial muscles (trunk) and caused limitation in bending and walking in nine patients. Fear of dropping an object because they could not bend to pick it up if alone was common. Asymmetric onset with predominance of stiffness in one leg and superimposed spasms on the same leg causing limping (stiff-leg syndrome)8,9⇓ was noted in 15 of 20 patients. The rigidity was at first fluctuating but then became fixed, resulting in abdominal wall rigidity, hyperlordosis, and frequent falls. Falls averaged 3 to 4/month especially when patients were anxious or stressed. Ten patients had breathing difficulty, precipitated by fear and anxiety, due to chest restriction and stiffness in the thoracic muscles.

Signs.

On examination, increased tone in the paraspinal muscles (a hallmark diagnostic sign) was noted in all patients. Hyperlordosis and co-contractures of the abdominal and thoracic paraspinals (figure 1) was prominent. On palpation, these muscles were very tight. In several patients, lumbar puncture could be done only under fluoroscopy due to severe tightness. In one patient it could not be done even under fluoroscopy. Stiffness in the legs was usually asymmetric (table 1) . In three patients, the stiffness was present only in one leg (stiff-leg syndrome). In 13 of 20 patients there was stiffness in the facial muscles causing, at times, a mask-like appearance. One patient had prominent stiffness in the cervical paraspinal muscles that spread upward and downward after stress or unexpected noises. The strength was normal. The tone was increased throughout the extremity in a global fashion. There was no cogwheel rigidity or spasticity, as seen with extrapyramidal or pyramidal tract involvement. The reflexes were increased 2 to 3+ in eight patients; Babinski was intermittently present in two. The gait was stiff, deliberate, and slow. Some patients could not initiate gait and others were afraid to walk without a cane or walker. Despite normal strength, stiffness was disabling. Twelve patients need a cane to walk, and seven a walker (see table 1). Assistive devices were necessitated by 1) fear initiating a gait without holding on to something; 2) truncal stiffness that precipitated sudden falls “en bloc”; 3) fear of falling on sudden and unexpected stimuli, such as when crossing a street unprotected in front of an oncoming car, or walking across a long hall; and 4) fear of falling caused by sudden or reflex spasms in trunk and legs.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Prominent hyperlordosis with co-contracture of the thoracolumbar paraspinals (A) and abdominal muscles (B) is characteristically seen in a woman with stiff-person syndrome.

View this table:
  • View inline
  • View popup
Table 1.

Neurologic signs in 20 patients with stiff-person syndrome

Spasms.

The episodic spasms were sudden or reflex, varied in severity, and were provoked by unexpected tactile stimuli, sudden noises, emotional upset, or fear of open spaces. Spasms were painful in eight and very painful in one. Marked anxiety, obsession with details, and task-specific phobias were noted in 10 patients. Some patients had experienced severe spasms for which they had to visit an emergency room for IV therapy with diazepam. One of our patients, 24 hours before admission, developed intense generalized muscle spasms lasting over 1 hour each. He became markedly diaphoretic, hypertensive, and tachycardic, with a drop in pulse oxygen. He was in a “status spasticus” for several days with intermittent generalized spasms involving initially the left leg followed by the truncal and appendicular muscles that necessitated IV boluses of diazepam every 1.5 hours, reaching up to 90 mg daily. Decreased sensory input (dark room, quiet nursing care, attention to avoid unexpected stimuli) and decreased voluntary movements terminated these life-threatening spasms only after 2 weeks of hospitalization. Although very closely monitored, he was not transferred to the intensive care unit because the noises and foreign environment of the unit could have worsened the spasms and made them more difficult to control.

Assessment of stiffness.

Data for reproducibility and validation of stiffness and spasms, collected blindly monthly for 4 months in five patients, had a very wide range among patients and within patients in reference to timed activities, degree of bending, and chest expansion. Two elements of stiffness and spasms, however—the heightened sensitivity and distribution of stiffness—gave reproducible scores with minimal SD. The mean heightened sensitivity scores during the 3-month period were 5.2 ± 0.49 and the number of stiff areas 5.4 ± 0.25 (figure 2) . The validity of these parameters is strengthened by the fact that their assessment was made blindly while the patients were randomized to placebo.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Mean number of heightened sensitivity rating (A) and stiff areas (B) for five patients with stiff-person syndrome evaluated monthly for 4 consecutive months. The scores of heightened sensitivity and stiff areas remain constant (5 ± 0.49 and 5.4 ± 0.25, respectively).

Associated conditions and autoantibodies.

Eight patients had IDDM, eight others thyroid disease, three pernicious anemia, one celiac disease, and one other notalgia paresthetica. Four patients had seizures. Transient CK elevation (two-to fourfold) was noted in 5 of 20 patients; one of them had mild muscle weakness. Muscle biopsy in two patients with persistent CK elevation showed histologic features suggestive of polymyositis with CD8+ T cells invading MHC-I-expressing muscle fibers (data not shown). Seven patients had family history of IDDM, four had thyroid disease, and one each had family history of systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, and vitiligo. Except for anti-GAD antibodies at high titers as described,4 various autoantibodies were also present, including antinuclear (1:80 to 1:12800) in six; antithyroid in six others; antiparietal cell in four; and against RNP, Jo-1, intrinsic factor, and anti-gliadin in four others. One patient had a monoclonal IgGk gammopathy of unknown significance.

Immunogenetics.

The most frequent alleles were associated with DR haplotypes (table 2 ); the DRβ1 0301 allele was noted in 8 of 18 patients (44%), which is higher than the frequency of this allele in the white populations of 1,331 examined white subjects (13%, p < 0.01). No significant HLA-DR association was found for the other alleles. When the three African American patients were excluded because the frequency of DRβ1 alleles in normal people of this race is not known, the frequency of DRβ1 0301 allele among all white patients with SPS was 70.5%, compared to 13% in the controls.

View this table:
  • View inline
  • View popup
Table 2.

Immunogenetic studies and allele association in patients with stiff-person syndrome

Discussion.

Based on observations in 20 bona-fide patients with SPS selected because of high titer anti-GAD-65 antibodies, several overlooked points have emerged regarding the clinical picture of SPS, its association with other disorders, and objective means of assessing stiffness and spasms.

SPS affects women more often than men (70% in our series); hence the preference for the more appropriate term “stiff-person syndrome.” Although a hallmark diagnostic sign remains the presence of hyperlordosis and co-contractures of the abdominal and thoracic paraspinal muscles, asymmetric presentation with predominance of stiffness in one leg was very common. Whether “stiff-limb” syndrome is a separate subset of SPS, as proposed,8,9⇓ is unclear because all our patients who started asymmetrically progressed to generalized symptomatology. A previously unrecognized sign is the stiffness in the facial muscles that was present in 70% of the patients. Due to reduced facial expression, one of the patients was initially diagnosed and treated for Parkinson disease.

SPS remains not only a clinical diagnosis but also a diagnosis of exclusion; hence the delay in reaching early diagnosis by as many as 18 years (mean 6.2 years). A primary diagnosis of anxiety and phobias was common. In five SPS patients, task-specific phobias were prominent, resulting in the initial diagnosis of “phobic neurosis”; in some of them, only in retrospect was the proper diagnosis made when benzodiazepines, prescribed for the phobias, improved gait and mobility. Two patients were misdiagnosed with multiple sclerosis (spinal MS) supported by the presence of oligoclonal bands in the CSF, which are frequently found in SPS patients (unpublished observations).

SPS can be serious or disabling. As shown in table 1, some patients sustain frequent falls and injuries, others use walkers or wheelchairs, and still others are bedridden due to severe stiffness, necessitating vigilance in early diagnosis and initiation of therapy. Sudden death and paroxysmal autonomic dysfunction have also been reported.15

Although the cause of the disease is unknown and the role of autoantibodies debated,16 a series of observations strengthens the autoimmune hypothesis.10-13,17-19⇓⇓⇓⇓⇓⇓ Various nonspecific autoantibodies and an association with autoimmune diseases such as thyroid, IDDM, and gastrointestinal autoimmune conditions were noted in our series. Elevation of CK, initially attributed to stiffness, was also observed in 5 of 20 patients but muscle biopsy in two of them showed mild endomysial inflammation with immunopathologic findings identical to polymyositis (unpublished observations). A very strong association with alleles in the DR and DQ phenotypes, which are often associated with IDDM, myasthenia gravis, inflammatory bowel disease, autoimmune hepatitis, systemic lupus erythematosus, and inclusion body myositis,20-23⇓⇓⇓ was also observed. A common immunogenetic background has been noted for both IDDM and SPS due to overlapping alleles in the HLADRβ1 and DQβ1 loci in more than 75% of patients with IDDM and SPS, which coincides with the presence of anti-GAD antibodies in both conditions.10-12,17-19⇓⇓⇓⇓⇓ There are distinct differences, however, in the anti-GAD antibody titers and the recognition of immunoreactive epitopes in the GAD antigen between SPS and IDDM that explain why the incidence of SPS in IDDM is low (about 1:10,000).17,18⇓ The observation that GAD activity and synthesis of GABA are directly inhibited in vitro by the anti-GAD–specific IgG from SPS patients but not by the IgG from GAD-negative SPS patients24,25⇓ has strengthened the immunopathogenic role of these antibodies. The occurrence of seizures, noted in four of our patients, is also consistent with the reduced brain GABA, presumably due to anti-GAD antibodies,26 that we have found in the brains of patients with SPS. A reduction of GABA in the brain and CSF has been associated with increased incidence of seizures or poor seizure control in epileptic patients.27 The seizures in our patients were well controlled with anticonvulsants that enhance GABA, such as gabapentin, which also help the symptomatology of SPS.

Based on reduced GABA due to anti-GAD antibodies, two types of therapies had been used by our patients; one with agents that potentiate the action of GABA, and the other with immunotherapies. Diazepam, which increases the frequency of opening of the GABAA receptor and leads to hyperpolarization, was the most effective drug used by 14 of 20 patients. Baclofen was used by six patients and gabapentin by two. Clonazepam, dantrium, and vigabatrin had been tried each by two patients with mild benefit. Plasma exchange or IVIg have been reported to benefit patients with SPS,12,28-30⇓⇓⇓ but they had not been used in any of our patients at the time of initial assessment. A number of our patients, however, have participated in a controlled study using high-dose IVIg. The study is now completed and the results analyzed.

  • Received April 6, 2000.
  • Accepted August 2, 2000.

References

  1. ↵
    Moersh FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome): report of a case and some observations in 13 other cases. Mayo Clin Proc . 1956; 31: 421–427.
    OpenUrlPubMed
  2. ↵
    McEvoy K. Stiff-man syndrome. Semin Neurol . 1991; 11: 197–205.
  3. ↵
    Toro CJD, Hallett M. Stiff-man syndrome. Semin Neurol . 1994; 154: 157–158.
    OpenUrl
  4. ↵
    Dalakas MC. Clinical symptomatology of stiff-person syndrome. In: Levy LM, moderator. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999;131:522–530.
  5. ↵
    Meinck HM, Ricker K, Hulser PJ, et al. Stiff man syndrome: neurophysiological findings in eight patients. J Neurol . 1995; 242: 134–142.
    OpenUrlCrossRefPubMed
  6. ↵
    Floeter MK. Inhibitory pathways defined by electrophysiology. In: Levy LM, moderator. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999;131:522–530.
  7. ↵
    Floeter MK, Valls–Sole J, Toro C, et al. Physiologic studies of spinal inhibitory circuits in patients with stiff-person syndrome. Neurology . 1998; 51: 85–93.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Barker RA, Revesz T, Thom M, et al. Review of 23 patients affected by the stiffman syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry . 1998; 65: 633–640.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Brown P, Marsden CD. The stiff man and stiff man plus syndromes. J Neurol . 1999; 246: 648–652.
    OpenUrlCrossRefPubMed
  10. ↵
    Solimena M, Folli F, Denis–Donini S, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med . 1988; 318: 1012–1020.
    OpenUrlPubMed
  11. ↵
    Solimena M, Folli F, Aparisi R, et al. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med . 1990; 322: 1555–1560.
    OpenUrlCrossRefPubMed
  12. ↵
    Brashear R, Phillips II HL. Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff-man syndrome. Neurology . 1991; 41: 1588–1592.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Dalakas MC. Autoantibodies and immunopathogenesis of the stiff-person syndrome. In: Levy LM, moderator. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999;131:522–530.
  14. Park MS, Tonai R. Phenotype frequencies of the class II (DR, DQ) DNA alleles by the pattern of sequence-specific primer mixtures (SSPM) in four different populations and probable haplotypes between DRB1 allele and DQB1 allele. In: Terasaki and Cecka, eds. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1992:475–500.
  15. ↵
    Mitsumoto H, Schwartzman MJ, Estes ML, et al. Sudden death and paroxysmal autonomic dysfunction in stiff-man syndrome. J Neurol . 1991; 238: 91–96.
    OpenUrlCrossRefPubMed
  16. ↵
    Kissel JT, Elble RJ. Stiff-person syndrome: stiff opposition to a simple explanation. Neurology . 1998; 51: 11–14.
    OpenUrlFREE Full Text
  17. ↵
    Ellis MT, Atkinson AM. The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat Med . 1996; 2: 148–153.
    OpenUrlCrossRefPubMed
  18. ↵
    Dew K, Ujihara N, Atkinson M, et al. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol . 1996; 156: 818–825.
    OpenUrlAbstract
  19. ↵
    Kelly H, McCann VJ, Kay PH, et al. Susceptibility to IDDM is marked by MHC supratypes rather than individual alleles. Immunogenetics . 1985; 22: 643–651.
    OpenUrlCrossRefPubMed
  20. ↵
    Koffman BM, Sivakumar K, Simonis T, et al. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol . 1998; 84: 139–142.
    OpenUrlCrossRefPubMed
  21. ↵
    Czaja AJ, Santrach PJ, Moore SB. HLA-DQ association in type 1 autoimmune hepatitis. Mayo Clin Proc . 1995; 70: 1154–1160.
    OpenUrlCrossRefPubMed
  22. ↵
    Dawkins RL, Christiansen FT, Kay PH, et al. Disease associations with complotypes, supratypes and haplotypes. Immunol Rev . 1983; 70: 5–22.
    OpenUrlCrossRef
  23. ↵
    Drachman DB, Adams RN, Josifek LF, et al. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med . 1982; 307: 769–775.
    OpenUrlCrossRefPubMed
  24. ↵
    Dinkel K, Meinck HM, Jury KM, et al. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol . 1998; 44: 194–201.
    OpenUrlCrossRefPubMed
  25. ↵
    Ishida K, Mitoma H, Song Si-y, et al. An elective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol 1999;46:263–267.
  26. ↵
    Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med . 1999; 131: 522–530.
    OpenUrlCrossRefPubMed
  27. ↵
    Petroff OA, Rothman DL, Behar KL, et al. Low Brain GABA level is associated with poor seizure control. Ann Neurol . 1996; 40: 908–911.
    OpenUrlCrossRefPubMed
  28. ↵
    Vicari AM, Folli F, Pozza G, et al. Plasmapheresis in the treatment of stiff-man syndrome. N Engl J Med . 1989; 320: 1499.Letter.
    OpenUrlPubMed
  29. ↵
    Amato AA, Cornman EW, Kissel JT. Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology . 1994; 44: 1652–1654.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Barker RAMC. Successful treatment of stiff-man syndrome with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry . 1997; 62: 426.
    OpenUrlFREE Full Text

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise